NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $57.48 +0.56 (+0.98%) Closing price 04:00 PM EasternExtended Trading$58.58 +1.10 (+1.91%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Travere Therapeutics Stock (NASDAQ:TVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$56.65▼$58.7550-Day Range$40.10▼$59.0352-Week Range$14.44▼$60.10Volume1.87 million shsAverage Volume2.19 million shsMarket Capitalization$5.35 billionP/E RatioN/ADividend YieldN/APrice Target$52.08Consensus RatingModerate Buy Company Overview Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market. The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult and pediatric patients with focal segmental glomerulosclerosis (FSGS). Travere is also pursuing regulatory submissions for sparsentan in immunoglobulin A nephropathy (IgAN), with ongoing clinical trials exploring its long-term safety and efficacy. In addition to its renal pipeline, Travere has expanded its portfolio through a collaboration with Reata Therapeutics to develop anion transport modulators for pediatric cystic fibrosis. Originally known as Retrophin, the company rebranded as Travere Therapeutics in December 2020 to better reflect its specialized focus on rare kidney diseases. Since the rebranding, Travere has advanced multiple late‐stage clinical programs and established a commercial infrastructure to support the launch and distribution of its therapies. The company maintains partnerships with academic research centers, patient advocacy organizations and global regulatory bodies to accelerate development timelines. Headquartered in San Diego, Travere serves patients primarily in the United States while conducting clinical trials and seeking regulatory approvals in Europe and other international markets. The company’s leadership team is led by President and Chief Executive Officer Stacy Ennis, who brings extensive experience in biotechnology and rare disease drug development. Under her direction, Travere continues to build its pipeline and support communities impacted by rare and serious conditions.AI Generated. May Contain Errors. Read More Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreTVTX MarketRank™: Travere Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 557th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.Downside RiskTravere Therapeutics has a consensus price target of $52.08, representing about 9.4% downside from its current price of $57.48.Amount of Analyst CoverageTravere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($0.25) to $1.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -249.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -249.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 44.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.12% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.39.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 4.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. News and Social Media4.6 / 5News Sentiment1.38 News SentimentTravere Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Travere Therapeutics this week, compared to 5 articles on an average week.Search Interest10 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,184,428.00 in company stock.Percentage Held by Insiders4.44% of the stock of Travere Therapeutics is held by insiders.Percentage Held by InstitutionsTravere Therapeutics has minimal institutional ownership at this time.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Stock News HeadlinesTravere Therapeutics: Filspari Is Becoming A Rare Kidney Disease PlatformJuly 3 at 5:00 AM | seekingalpha.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by BrokeragesJuly 3 at 2:29 AM | americanbankingnews.comThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history. George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline.July 6 at 1:00 AM | Eagle Publishing (Ad)Travere Therapeutics (NASDAQ:TVTX) Director Roy Baynes Sells 4,500 SharesJune 17, 2026 | insidertrades.comTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027June 16, 2026 | businesswire.comIs Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comTravere Therapeutics (TVTX) Gets a Buy from Wells FargoJune 12, 2026 | theglobeandmail.comTravere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines - SlideshowJune 8, 2026 | seekingalpha.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $38.21 at the start of the year. Since then, TVTX stock has increased by 50.4% and is now trading at $57.48. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings results on Monday, May, 4th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics's revenue for the quarter was up 55.6% on a year-over-year basis. Read the conference call transcript. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO). Company Calendar Last Earnings5/04/2026Today7/06/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TVTX's financial health is in the Green zone, according to TradeSmith. TVTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVTX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees460Year Founded2011Price Target and Rating Average Price Target for Travere Therapeutics$52.08 High Price Target$70.00 Low Price Target$25.00 Potential Upside/Downside-9.4%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.55 million Net Margins-4.00% Pretax Margin-8.36% Return on Equity-26.16% Return on Assets-3.71% Debt Debt-to-Equity Ratio3.16 Current Ratio3.13 Quick Ratio3.08 Sales & Book Value Annual Sales$490.73 million Price / Sales10.89 Cash Flow$0.37 per share Price / Cash Flow157.18 Book Value$1.28 per share Price / Book44.91Miscellaneous Outstanding Shares92,990,000Free Float88,864,000Market Cap$5.35 billion OptionableOptionable Beta1.10 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:TVTX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
